11.19
+0.11(+0.99%)
Currency In USD
| Previous Close | 11.08 |
| Open | 11.06 |
| Day High | 11.28 |
| Day Low | 10.9 |
| 52-Week High | 17.43 |
| 52-Week Low | 5.6 |
| Volume | 2.37M |
| Average Volume | 3.22M |
| Market Cap | 835.25M |
| PE | 14.35 |
| EPS | 0.78 |
| Moving Average 50 Days | 11.56 |
| Moving Average 200 Days | 11.18 |
| Change | 0.11 |
If you invested $1000 in CorMedix Inc. (CRMD) 10 years ago, it would be worth $906.07 as of November 12, 2025 at a share price of $11.19. Whereas If you bought $1000 worth of CorMedix Inc. (CRMD) shares 5 years ago, it would be worth $1,956.29 as of November 12, 2025 at a share price of $11.19.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025
GlobeNewswire Inc.
Oct 31, 2025 12:30 PM GMT
BERKELEY HEIGHTS, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it
CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath
GlobeNewswire Inc.
Oct 23, 2025 12:30 PM GMT
BERKELEY HEIGHTS, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that De
CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance
GlobeNewswire Inc.
Oct 20, 2025 11:30 AM GMT
‒ Q3 2025 Unaudited Pro Forma Net Revenue of more than $125 million ‒ ‒ Q3 2025 Unaudited DefenCath Net Revenue of more than $85 million ‒ ‒ Raising FY 2025 Pro Forma Net Revenue Guidance to at least $375 million ‒ ‒ ~$30mm of operating synergy on a